Retatrutide: Uses, Benefits, Dosage and Safety

Retatrutide is an experimental once-weekly injection for obesity, developed by Eli Lilly under the code LY3437943. It acts on three hormone receptors at once, which is one more than any medicine currently licensed for weight loss.

The reason it is discussed everywhere is the size of the result. In its phase 3 programme it produced an average weight reduction of 28.3% at 80 weeks, and nearly half of the participants on the highest dose lost at least 30% of their body weight. Those are figures that used to belong to bariatric surgery.

The part usually left out is that none of this has been reviewed by a regulator yet. Lilly has said it intends to file in the first quarter of 2027, so every number below describes what happened inside a trial, not what a prescriber can currently write on a script.

What is retatrutide?#

Retatrutide is a synthetic peptide built to bind three receptors that the body already uses to regulate appetite, insulin and energy use. It is given as a subcutaneous injection once a week.

If the vocabulary here is unfamiliar, what peptides actually are covers the ground this article assumes.

Where it comes from#

It is a laboratory construct rather than anything isolated from tissue. The molecule is loosely modelled on GIP, with a fatty acid chain attached so that it binds to albumin in the blood and clears slowly enough to be dosed weekly. That once-weekly schedule is a design decision rather than a property of the hormone it resembles.

The compound entered human trials around 2019 and reported its phase 2 results in the New England Journal of Medicine in 2023. Its phase 3 programme, TRIUMPH, reported through 2026.

Proposed mechanisms of action#

Three receptors, each doing a different job.

• GLP-1. The receptor semaglutide acts on. Activating it slows stomach emptying and reduces appetite signalling in the brain, so meals end sooner and hunger returns later.
• GIP. The second receptor tirzepatide adds. Its contribution to weight loss is still argued over, and it appears to improve how well the body handles fat and sugar after eating, and to reduce nausea from GLP-1 activity.
• Glucagon. The one that makes retatrutide different. Glucagon signalling raises energy expenditure and mobilises fat stored in the liver.

That third receptor is the whole design. The GLP-1 and GIP arms reduce how much a person eats. The glucagon arm raises how much they burn. Attacking both sides of the balance is why the trial results are larger than the drugs that only work on intake.

There is a complication worth stating plainly, because it is the objection every endocrinologist raises first: glucagon also raises blood sugar. That is its job in a fasting body. Adding it to a diabetes drug looks self-defeating, and the trial data indicates the two incretin arms more than compensate, with blood sugar improving rather than worsening.

What retatrutide is claimed to do#

Substantial weight loss#

The claim, in plain terms, is that a person loses considerably more weight than they would on any drug currently available, and keeps losing it for longer before the curve flattens.

In the TRIUMPH-1 trial, agonism at the GLP-1, GIP and glucagon receptors produced a mean body weight reduction of 28.3% on the 12 mg dose at 80 weeks, with 45.3% of participants reaching a loss of 30% or more.

In practice that describes a person of 110 kg finishing the trial somewhere near 79 kg. Not a trimmed version of the same body, but a different clothing size, a different resting heart rate, and in many cases a different set of prescriptions. The 30% threshold matters because it is roughly where the weight loss from surgery begins.

This was measured in adults with obesity, across five completed phase 3 trials, over 80 weeks with an extension to 104. TRIUMPH-2, TRIUMPH-3 and TRIUMPH-4 reported mean reductions of 20.8%, 22.6% and 28.7%. Participants starting at a BMI of 35 or above reached an average of 30.3% at two years.

Better blood sugar control#

The claim is that a person with type 2 diabetes sees their long-term blood sugar marker fall substantially, alongside the weight.

The GLP-1 and GIP arms both increase insulin release in response to a meal and reduce glucagon's effect on the liver's sugar output, which is the standard incretin mechanism.

Put another way, the pancreas responds more briskly when food arrives, and the liver is less inclined to push stored sugar into the blood between meals. The two together lower the average blood sugar that HbA1c measures.

This was measured in TRANSCEND-T2D-1, where the reported reduction in HbA1c reached 2.0 percentage points at 40 weeks. That is a large figure in diabetes terms, where a single percentage point is a meaningful result.

Less knee pain#

The claim is that a painful arthritic knee hurts less, and the reason is mostly mechanical rather than pharmacological.

There is no direct action on cartilage or on joint inflammation in the proposed mechanism. The route is load: a knee carrying 30 kg less through every step is a knee under less stress.

What that looks like to a person is stairs becoming possible again, and the pain that arrives at the end of a day arriving later or not at all.

Lilly reported knee osteoarthritis pain reductions of up to 4.3 points on a standard scale in the TRIUMPH-4 and related trials. This is a secondary outcome in an obesity programme rather than the result of a trial designed around knees.

Fewer breathing interruptions in sleep#

The claim is that obstructive sleep apnoea becomes less severe, measured as fewer breathing interruptions per hour of sleep.

The mechanism is again indirect. Fat around the neck and pharynx narrows the airway, and the airway collapses more readily during sleep as a result. Reducing that tissue widens the margin.

For a person, the difference between severe and moderate apnoea is the difference between waking unrefreshed every day and occasionally sleeping through.

In the same programme, sleep apnoea severity fell by up to 36.1 events per hour. That was measured in participants who had apnoea at the start, not in everyone enrolled.

Improvement in fatty liver#

The claim is that fat accumulated in the liver is reduced, which matters because that accumulation is the first step toward more serious liver disease.

Glucagon receptor agonism increases the rate at which the liver oxidises its own stored fat, so the glucagon arm acts on the liver directly rather than only through weight loss.

The claim, stripped of the biology, is that the organ empties out its fat faster than it takes it in. This is one of the few effects here where the third receptor does something the other two cannot.

The phase 2 trial measured liver fat by MRI and reported substantial reductions in participants who had raised liver fat at baseline. The phase 3 liver programme has not reported in full.

What the evidence actually supports#

The evidence base here is genuinely strong, and it is a different shape from most of the compounds on this site.

• Species and route. Human, at the route people would actually use. There is no inference from rodents required, which is unusual enough on this subject to be worth stating.
• Concentration of sources. Nearly all of it comes from one sponsor, Eli Lilly, and its contracted trial sites. That is normal for a drug at this stage and it is still the single most important fact about the evidence base. The independent replication that follows a licence has not happened.
• Human data. Five completed phase 3 trials with published topline results, plus a phase 2 trial published in full in the New England Journal of Medicine. Toplines are not the same as full publications, and for most of TRIUMPH the full papers are still to come.
• What has not been looked at. Cardiovascular outcomes, which semaglutide has and retatrutide does not. Use beyond two years. The head-to-head trial against tirzepatide is running rather than finished, so every comparison below is between separate trials with different participants.

The honest summary is that the weight loss figures are as solid as pre-approval figures get, and the questions that remain are about durability, hard outcomes and independent confirmation rather than about whether the drug works.

Side effects and safety profile#

Most of what was reported is the familiar incretin picture: nausea, diarrhoea, constipation and vomiting, mostly mild to moderate, rising with dose and largely settling as treatment continues. This is the same profile semaglutide and tirzepatide produce, and the dose-escalation schedules used in the trials exist to blunt it.

One finding is specific to this drug rather than the class. Roughly one in eight participants on the higher doses reported dysesthesia, an altered or unpleasant skin sensation, against almost none on placebo. Lilly describes these events as generally mild and mostly resolving. It is dose-related, it does not appear with the two-receptor drugs, and it is the most distinctive safety signal in the programme.

Heart rate increased modestly, as it does across the incretin class. Since retatrutide is not licensed anywhere, there is no approved label listing contraindications, and the exclusion criteria of the trials are currently the closest thing to one.

How it is dosed and administered#

Retatrutide has no approved dose, because it has no approval. What follows describes the trials.

In the TRIUMPH programme it was given as a once-weekly subcutaneous injection, with the dose stepped up gradually over several months to reduce nausea, in the same pattern the licensed incretin drugs use. The arms that produced the headline results were 4 mg, 9 mg and 12 mg. The phase 2 trial ran arms up to 12 mg as well, reaching 24.2% mean weight reduction at 48 weeks.

Protocols circulating outside clinical settings typically report copying that escalation schedule. It is worth being clear about what those numbers are: they are trial doses lifted from a programme in which participants were screened for exclusions, monitored for adverse events, and had the compound's identity and concentration guaranteed. None of those conditions travels with the number.

Nothing about identity or concentration can be assumed from a label. Third-party testing and what a COA proves covers what a certificate does and does not establish, and storing and handling peptides correctly covers the conditions under which a peptide degrades. If technique is the question, the practical guides cover it separately.

Retatrutide compared with tirzepatide and semaglutide#

Against tirzepatide#

Tirzepatide acts on two of the same three receptors and reached roughly 20% average weight loss in SURMOUNT-1. Retatrutide reported up to 28.3% in TRIUMPH-1. The comparison is between separate trials rather than a head-to-head, so the gap is suggestive rather than measured, and the direct trial has not reported.

The practical difference is availability. Tirzepatide is licensed and prescribed today. Retatrutide is not licensed anywhere.

Against semaglutide#

Semaglutide reached about 15% in the STEP programme, so on weight alone the gap is large. On hard outcomes it runs the other way: semaglutide has a completed cardiovascular outcomes trial showing reduced heart attacks and strokes, and retatrutide has nothing equivalent.

Weight loss is a surrogate. It is a good surrogate, and it is still not the same as a trial that counted heart attacks.

Against cagrilintide#

Cagrilintide works through amylin rather than the incretin receptors, and is being developed in combination with semaglutide rather than alone. It is the nearest thing to a competing mechanism rather than a competing molecule.

Frequently asked questions#

Is retatrutide better than tirzepatide?

On average weight loss in separate trials, the retatrutide figures are higher. The head-to-head trial that would settle it is running and has not reported, and comparing across trials with different participants and different durations is the least reliable form of comparison there is.

When will it be available?

Lilly has said it plans to file for US approval in the first quarter of 2027. A decision would follow some months after that, so late 2027 is the earliest plausible point, and regulatory timelines slip more often than they hold.

What is the skin sensation side effect?

Dysesthesia: an altered, often unpleasant sensation in the skin, reported by around one in eight participants on the higher doses. It is dose-related, mostly mild, mostly resolving, and it is specific to this compound rather than to the class.

Does the weight come back if you stop?

Nobody has published a withdrawal trial for retatrutide specifically. For every other drug in this class that has been studied, weight returns substantially after stopping, because the drugs treat appetite while they are present rather than resetting anything.

How is it different from a compounded or research-labelled vial?

The trial results describe a molecule of verified identity and concentration. A vial obtained elsewhere shares a name with it and nothing else is established. How to read a peptide study without being fooled is about the gap between what a trial shows and what a claim about a product implies.

Key takeaways#

• Retatrutide is an experimental triple agonist acting on GLP-1, GIP and glucagon receptors. It is not approved anywhere, and a US filing is planned for early 2027.
• Phase 3 reported an average 28.3% weight reduction at 80 weeks on the 12 mg dose, with 45.3% of participants losing 30% or more of their body weight.
• The glucagon receptor is what distinguishes it. It raises energy expenditure and mobilises liver fat, so the drug works on both sides of the energy balance rather than on intake alone.
• Side effects are mostly the usual incretin gastrointestinal profile. Dysesthesia, an altered skin sensation, affected about one in eight on higher doses and is specific to this drug.
• The evidence comes almost entirely from one sponsor, cardiovascular outcomes have not been tested, and the head-to-head against tirzepatide has not reported.

References#

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023.
2. Eli Lilly. Lilly's triple agonist retatrutide delivered powerful weight loss. TRIUMPH-1 topline results.
3. Eli Lilly. Retatrutide drove substantial improvements in knee osteoarthritis pain and sleep apnoea. TRIUMPH-4 and related trials.
4. The compound page on this site: retatrutide.